Covaris

The group aims to provide solutions for all stages of proteomics research and address "critical unmet needs in biomarker and drug target discovery, personalized medicine, drug profiling, and selective reaction monitoring."

Caliper CEO Kevin Hrusovsky said the deal is a "logical next step" because many laboratories are already using both Covaris' shearing technology with Caliper's tools like the Sciclone NGS Workstation.

The firms will offer a combination of their sample prep technologies for next-generation sequencing workflows.

The firms will co-market Covaris' Adaptive Focused Acoustics systems with Tecan's Freedom EVO liquid handling instruments.

At a recent conference, two members of the Broad's process development team shared some of the changes that have made sample prep faster, cheaper, and more high-throughput.

Under the terms of the agreement, the companies will co-market Covaris' DNA-shearing technology with Illumina's sequencing product line, including the Genome Analyzer, HiSeq 2000, and HiScanSQ.

The firms will co-market Illumina's sequencing instruments with Covaris' sample prep technology.

The agreement covers Agilent's target enrichment and Covaris' DNA shearing technology.

Under the agreement, Agilent will market Covaris' S2 DNA shearing system for use with its SureSelect Target Enrichment System, a solution-based DNA selection method for high-throughput sequencing.

Shire Owings Mills (Md.) Plant, Alexandria Real Estate Equities, Takeda Pharmaceutical, Wareham Development, PATH, Fall River (Mass.) Executive Park, University of Massachusetts/Dartmouth Bioprocessing Facility, Silicon Border, Sapphire Engineering, Campanelli Business Park, University of California-Davis M.I.N.D., Institute, Doe & Ingalls of North Carolina, Covaris, Life Technologies, BioMed Realty Trust, Shasun Pharma Solutions

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.